From Our 2014 Archives
FDA Approves Inhaled Insulin Drug Afrezza
Latest Diabetes News
By Valarie Basheda
Reviewed by Brunilda Nazario, MD
The insulin, called Afrezza, is a rapid-acting insulin and is meant to be taken at mealtime or soon after.
"Today's approval broadens the options available" for delivering insulin in people with diabetes, Jean-Marc Guettier, MD, director of the FDA's Division of Metabolism and Endocrinology Products, says in a news release.
The FDA estimates that 18.1 million people have diabetes. About 7 million more are undiagnosed, the agency says.
This is the third time the drug was up for FDA approval. Its maker, MannKind Corporation, conducted additional safety studies after the first two attempts.
Patients with type 1 diabetes will need to use the drug in combination with long-acting insulin. Patients with type 2 diabetes will use it in combination with oral medications.
Afrezza carries a warning as it may cause a sudden tightening of the chest. It is not recommended for people with asthma or COPD. It is also not recommended for people that smoke or for the treatment of diabetic ketoacidosis.
SOURCE: FDA: "FDA Approves Afrezza to Treat Diabetes."
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions